Why is Glenmark Pharma falling/rising?

As of 28-Jul, Glenmark Pharmaceuticals Ltd. is currently priced at 2,143.45, reflecting an increase of 3.45 (0.16%). The stock has shown a strong performance over the last month, with a return of +24.71%, significantly outperforming the benchmark Sensex, which declined by -3.77% during the same period. However, there has been a recent decline in investor participation, as evidenced by a 22.27% drop in delivery volume compared to the 5-day average. Despite this, the stock maintains a solid position with a low Debt to EBITDA ratio of 1.00 times and has reported positive results for the last four consecutive quarters, including a remarkable 576.7% growth in PAT for the latest quarter. Additionally, high institutional holdings at 38.3% indicate strong confidence from knowledgeable investors.
In the broader market context, while Glenmark's short-term performance has been positive, it has experienced a slight decline of -2.01% over the past week, contrasting with the Sensex's smaller drop of -1.59%. This suggests that while the stock is generally performing well over longer periods, it is currently facing some short-term pressures. Nevertheless, its consistent returns over the past three years, including a 49.07% increase in the last year, highlight its resilience and ability to outperform the broader market, which has seen only a marginal gain of 3.52% year-to-date.